Sanofi Total Common and Preferred Stock Dividends Paid 2010-2024 | SNY
Sanofi annual/quarterly total common and preferred stock dividends paid history and growth rate from 2010 to 2024. Total common and preferred stock dividends paid can be defined as the cash outflow for all company dividends paid out to preferred and common shareholders.
- Sanofi total common and preferred stock dividends paid for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
- Sanofi total common and preferred stock dividends paid for the twelve months ending September 30, 2024 were $-9.986B, a 6.17% increase year-over-year.
- Sanofi annual total common and preferred stock dividends paid for 2023 were $-4.887B, a 8.69% increase from 2022.
- Sanofi annual total common and preferred stock dividends paid for 2022 were $-4.496B, a 6.31% decline from 2021.
- Sanofi annual total common and preferred stock dividends paid for 2021 were $-4.799B, a 5.52% increase from 2020.
Sanofi Annual Total Common and Preferred Stock Dividends Paid
(Millions of US $) |
| 2023 |
$-4,887 |
| 2022 |
$-4,496 |
| 2021 |
$-4,799 |
| 2020 |
$-4,547 |
| 2019 |
$-4,310 |
| 2018 |
$-4,472 |
| 2017 |
$-4,210 |
| 2016 |
$-4,183 |
| 2015 |
$-4,115 |
| 2014 |
$-4,900 |
| 2013 |
$-4,848 |
| 2012 |
$-4,497 |
| 2011 |
$-1,911 |
| 2010 |
$-4,158 |
| 2009 |
$-4,005 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$121.816B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
